Agios Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Agios Pharmaceuticals

30/07/2026 14:31

Agios Pharmaceuticals Inc AGIO.OQ reported a quarterly adjusted loss of $1.69​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.93.  The mean expectation of ten analysts for the quarter was for a loss of $1.67 per share. Wall Street expected results to range from $-2.01 to $-1.48 per share.
Revenue rose 259.3% to $44.75 million from a year ago; analysts expected $25.52 million. 
Agios Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.69​.
The company reported a quarterly loss of $100.7 million.
Agios Pharmaceuticals Inc shares had fallen by 5.7% this quarter and gained 28.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 3.8% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Agios Pharmaceuticals Inc is $46.00, about 23.9% above its last closing price of $35.01
This summary was machine generated from LSEG data July 30 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.67
-1.69
Missed
Mar. 31 2026 
-1.80
-1.69
Beat
Dec. 31 2025 
-1.95
-1.86
Beat
Sep. 30 2025 
-1.90
-1.78
Beat